This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mani, A. Articles by Gelmann, E. P. Search for Related Content PubMed PubMed Citation Articles by Mani, A. Articles by Gelmann, E. P.

The Ubiquitin-Proteasome Pathway and Its Role in Cancer

From the Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

Address reprint requests to E. Gelmann, MD, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Rd NW, Washington, DC 20007-2197; e-mail: Gelmanne{at}georgetown.edu

Critical cellular processes are regulated, in part, by maintaining the appropriate intracellular levels of proteins. Whereas de novo protein synthesis is a comparatively slow process, proteins are rapidly degraded at a rate compatible with the control of cell cycle transitions and cell death induction. A major pathway for protein degradation is initiated by the addition of multiple 76–amino acid ubiquitin monomers via a three-step process of ubiquitin activation and substrate recognition. Polyubiquitination targets proteins for recognition and processing by the 26S proteasome, a cylindrical organelle that recognizes ubiquitinated proteins, degrades the proteins, and recycles ubiquitin. The critical roles played by ubiquitin-mediated protein turnover in cell cycle regulation makes this process a target for oncogenic mutations. Oncogenes of several common malignancies, for example colon and renal cell cancer, code for ubiquitin ligase components. Cervical oncogenesis by human papillomavirus is also mediated by alteration of ubiquitin ligase pathways. Protein degradation pathways are also targets for cancer therapy, as shown by the successful introduction of bortezomib, an inhibitor of the 26S proteasome. Further work in this area holds great promise toward our understanding and treatment of a wide range of cancers.

Supported in part by US Public Health Service grant Nos. ES09888 and CA96854 (E.P.G.).

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				J. A. Poff, C. T. Allen, B. Traughber, A. Colunga, J. Xie, Z. Chen, B. J. Wood, C. Van Waes, K. C. P. Li, and V. Frenkel Pulsed High-Intensity Focused Ultrasound Enhances Apoptosis and Growth Inhibition of Squamous Cell Carcinoma Xenografts with Proteasome Inhibitor Bortezomib Radiology, June 23, 2008; (2008) 2482071674. [Abstract] [Full Text]

				L. Wang, S. Kumar, B. L. Fridley, K. R. Kalari, I. Moon, L. L. Pelleymounter, M. A.T. Hildebrandt, A. Batzler, B. W. Eckloff, E. D. Wieben, et al. Proteasome {beta} Subunit Pharmacogenomics: Gene Resequencing and Functional Genomics Clin. Cancer Res., June 1, 2008; 14(11): 3503 - 3513. [Abstract] [Full Text] [PDF]

				S. Uddin, M. Ahmed, P. Bavi, R. El-Sayed, N. Al-Sanea, A. AbdulJabbar, L. H. Ashari, S. Alhomoud, F. Al-Dayel, A. R. Hussain, et al. Bortezomib (Velcade) Induces p27Kip1 Expression through S-Phase Kinase Protein 2 Degradation in Colorectal Cancer Cancer Res., May 1, 2008; 68(9): 3379 - 3388. [Abstract] [Full Text] [PDF]

				J. E. Rosenberg, S. Halabi, B. L. Sanford, A. L. Himelstein, J. N. Atkins, R. J. Hohl, F. Millard, D. F. Bajorin, E. J. Small, and For the Cancer and Leukemia Group B Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207 Ann. Onc., May 1, 2008; 19(5): 946 - 950. [Abstract] [Full Text] [PDF]

				R. Tan, W. He, X. Lin, L. P. Kiss, and Y. Liu Smad ubiquitination regulatory factor-2 in the fibrotic kidney: regulation, target specificity, and functional implication Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1076 - F1083. [Abstract] [Full Text] [PDF]

				S. J. Shah, S. Blumen, I. Pitha-Rowe, S. Kitareewan, S. J. Freemantle, Q. Feng, and E. Dmitrovsky UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation Mol. Cancer Ther., April 1, 2008; 7(4): 905 - 914. [Abstract] [Full Text] [PDF]

				B. Gold, T. Kirchhoff, S. Stefanov, J. Lautenberger, A. Viale, J. Garber, E. Friedman, S. Narod, A. B. Olshen, P. Gregersen, et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33 PNAS, March 18, 2008; 105(11): 4340 - 4345. [Abstract] [Full Text] [PDF]

				B. Guan, P. Pungaliya, X. Li, C. Uquillas, L. N. Mutton, E. H. Rubin, and C. J. Bieberich Ubiquitination by TOPORS Regulates the Prostate Tumor Suppressor NKX3.1 J. Biol. Chem., February 22, 2008; 283(8): 4834 - 4840. [Abstract] [Full Text] [PDF]

				S. Liu, Z. Liu, Z. Xie, J. Pang, J. Yu, E. Lehmann, L. Huynh, T. Vukosavljevic, M. Takeki, R. B. Klisovic, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-{kappa}B-dependent DNA methyltransferase activity in acute myeloid leukemia Blood, February 15, 2008; 111(4): 2364 - 2373. [Abstract] [Full Text] [PDF]

				J. Liu and R. Nussinov Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design PNAS, January 22, 2008; 105(3): 901 - 906. [Abstract] [Full Text] [PDF]

				P. van Tijn, F. M. S. de Vrij, K. G. Schuurman, N. P. Dantuma, D. F. Fischer, F. W. van Leeuwen, and E. M. Hol Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease J. Cell Sci., May 1, 2007; 120(9): 1615 - 1623. [Abstract] [Full Text] [PDF]

				F. Bianchi, A. Magnifico, C. Olgiati, N. Zanesi, Y. Pekarsky, E. Tagliabue, C. M. Croce, S. Menard, and M. Campiglio FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells PNAS, December 12, 2006; 103(50): 18981 - 18986. [Abstract] [Full Text] [PDF]

				J. Hur, D. W. Bell, K. L. Dean, K. R. Coser, P. C. Hilario, R. A. Okimoto, E. M. Tobey, S. L. Smith, K. J. Isselbacher, and T. Shioda Regulation of Expression of BIK Proapoptotic Protein in Human Breast Cancer Cells: p53-Dependent Induction of BIK mRNA by Fulvestrant and Proteasomal Degradation of BIK Protein. Cancer Res., October 15, 2006; 66(20): 10153 - 10161. [Abstract] [Full Text] [PDF]

				C. Chen, A. K. Seth, and A. E. Aplin Genetic and Expression Aberrations of E3 Ubiquitin Ligases in Human Breast Cancer Mol. Cancer Res., October 1, 2006; 4(10): 695 - 707. [Abstract] [Full Text] [PDF]

				R. Tan, J. Zhang, X. Tan, X. Zhang, J. Yang, and Y. Liu Downregulation of SnoN Expression in Obstructive Nephropathy Is Mediated by an Enhanced Ubiquitin-Dependent Degradation J. Am. Soc. Nephrol., October 1, 2006; 17(10): 2781 - 2791. [Abstract] [Full Text] [PDF]

				H. Jin, S. Li, and A. Villegas Jr. Down-Regulation of the 26S Proteasome Subunit RPN9 Inhibits Viral Systemic Transport and Alters Plant Vascular Development Plant Physiology, October 1, 2006; 142(2): 651 - 661. [Abstract] [Full Text] [PDF]

				C. Brignole, D. Marimpietri, F. Pastorino, B. Nico, D. Di Paolo, M. Cioni, F. Piccardi, M. Cilli, A. Pezzolo, M. V. Corrias, et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst, August 16, 2006; 98(16): 1142 - 1157. [Abstract] [Full Text] [PDF]

				R. Mazzanti, M. Solazzo, O. Fantappie, S. Elfering, P. Pantaleo, P. Bechi, F. Cianchi, A. Ettl, and C. Giulivi Differential expression proteomics of human colon cancer Am J Physiol Gastrointest Liver Physiol, June 1, 2006; 290(6): G1329 - G1338. [Abstract] [Full Text] [PDF]

				T. Taniguchi and A. D. D'Andrea Molecular pathogenesis of Fanconi anemia: recent progress Blood, June 1, 2006; 107(11): 4223 - 4233. [Abstract] [Full Text] [PDF]

				S. D. Desai, A. L. Haas, L. M. Wood, Y.-C. Tsai, S. Pestka, E. H. Rubin, A. Saleem, A. Nur-E-Kamal, and L. F. Liu Elevated Expression of ISG15 in Tumor Cells Interferes with the Ubiquitin/26S Proteasome Pathway Cancer Res., January 15, 2006; 66(2): 921 - 928. [Abstract] [Full Text] [PDF]

				S. E. Hartman, P. Bertone, A. K. Nath, T. E. Royce, M. Gerstein, S. Weissman, and M. Snyder Global changes in STAT target selection and transcription regulation upon interferon treatments Genes & Dev., December 15, 2005; 19(24): 2953 - 2968. [Abstract] [Full Text] [PDF]